drugset / Trial / NCT05004116

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

NCT05004116

Phase 1/2 Recruiting 77 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors. We researchers will try to find the highest dose of the study drug that causes few or mild side effects in study participants. When the researchers find this dose, we will evaluate it in a different group of participants to find out whether repotrectinib in combination with chemotherapy is an effective treatment for children and young adults who have advanced/metastatic solid tumors. Another purpose of the study is to look at the way the body absorbs, distributes, and gets rid of repotrectinib.

Timeline

Start
2021-08-09
Primary completion
2028-08
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Repotrectinib Small molecule Oral
Background Irinotecan Small molecule
Background Temozolomide Small molecule

Indications